A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | March 7, 2018 |
| End Date: | March 2020 |
| Contact: | Cameron Brennan, MD |
| Email: | brennac2@mskcc.org |
| Phone: | 212-639-8268 |
PET Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study
The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot
particles, can be used to take pictures of brain tumors. The investigators want to understand
how the particles are distributed and removed from the body, which may help others be treated
in the future. This will be the first time that 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles are
being used in people. The amount of particles given in this study is very small compared to
the amount that was used in mice animal studies.
particles, can be used to take pictures of brain tumors. The investigators want to understand
how the particles are distributed and removed from the body, which may help others be treated
in the future. This will be the first time that 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles are
being used in people. The amount of particles given in this study is very small compared to
the amount that was used in mice animal studies.
Inclusion Criteria:
- 18 years of age or older
- Histologically confirmed diagnosis of malignant primary brain tumor or known
metastatic cancer with brain lesion presumed to be metastatic.
- Normal baseline cardiac function based upon pre-operative evaluation at the physcian's
discretion
- All patients of childbearing age must use an acceptable form of birth control
- Women who are pre-menopausal must have a negative serum pregnancy test
Exclusion Criteria:
- Known pregnancy or breast-feeding Medical illness unrelated to the tumor which in the
opinion of the attending physician and principal investigator will preclude
administration of the tracer
°This includes patients with uncontrolled infection, chronic renal insufficiency,
myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias
other than chronic atrial fibrillation and chronic active or persistent hepatitis, or
New York Heart Association Classification III or IV heart disease
- More than one metastatic cancer active in the last 5 years
- Active metastatic cancer in addition to malignant primary brain tumor
- Weight greater than the 400-lb weight limit of the PET scanner
- Unmanageable Claustrophobia
- Inability to lie in the scanner for 30 minutes
We found this trial at
2
sites
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Cameron Brennan, MD
Phone: 212-639-8268
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials